Jenny Lesser Herbach
AeroLeads people directory · profile

Jenny Lesser Herbach Email & Phone Number

CEO & Co-Founder, Adventris Pharmaceuticals at Adventris Pharmaceuticals
Location: San Francisco, California, United States 17 work roles 5 schools
2 work emails found @amunix.com 1 phone found area 650 LinkedIn matched
✓ Verified Jul 2026 4 data sources Profile completeness 100%

Contact Signals · 2 work emails · 1 phone

Work email j****@amunix.com
Direct phone (650) ***-****
LinkedIn Profile matched
3 free lookups remaining · No credit card
Current company
Role
CEO & Co-Founder, Adventris Pharmaceuticals
Location
San Francisco, California, United States
Company size

Who is Jenny Lesser Herbach? Overview

A concise factual answer block for searchers comparing this professional profile.

Quick answer

Jenny Lesser Herbach is listed as CEO & Co-Founder, Adventris Pharmaceuticals at Adventris Pharmaceuticals, a with 5 employees, based in San Francisco, California, United States. AeroLeads shows a work email signal at amunix.com, phone signal with area code 650, and a matched LinkedIn profile for Jenny Lesser Herbach.

Jenny Lesser Herbach previously worked as CEO & Co-Founder at Adventris Pharmaceuticals and Director, Corporate Development & Product Strategy at Amunix. Jenny Lesser Herbach holds Mba from Harvard Business School.

Company email context

Email format at Adventris Pharmaceuticals

This section adds company-level context without repeating Jenny Lesser Herbach's masked contact details.

*@amunix.com
71% confidence

AeroLeads found 2 current-domain work email signals for Jenny Lesser Herbach. Compare company email patterns before reaching out.

Profile bio

About Jenny Lesser Herbach

Jenny Lesser Herbach is a CEO & Co-Founder, Adventris Pharmaceuticals at Adventris Pharmaceuticals. She possess expertise in strategy, financial modeling, biotechnology, oncology, cross functional team leadership and 14 more skills. Colleagues describe her as "Jenny has excellent interpersonal and cross-functional team leadership skills. I also found her market access marketing skills to be a great asset during the launch of Esbriet. She would make an excellent addition to any department."

Listed skills include Strategy, Financial Modeling, Biotechnology, Oncology, and 15 others.

Current workplace

Jenny Lesser Herbach's current company

Company context helps verify the profile and gives searchers a useful next step.

Adventris Pharmaceuticals
Adventris Pharmaceuticals
CEO & Co-Founder, Adventris Pharmaceuticals
Employees
5
AeroLeads page
17 roles · 26 years

Jenny Lesser Herbach work experience

A career timeline built from the work history available for this profile.

Director, Corporate Development & Product Strategy

Amunix
May 2019 - Jun 2022

Business Development Consultant

Flx Bio, Inc.
Jul 2018 - May 2019

Director Of Marketing

Alameda, California, Us

Feb 2016 - Jul 2018

Senior Manager, Value Marketing

Boulder, Co, Us

• Built value marketing function from scratch by identifying, hiring, and managing an agency and developing a strategic plan and accompanying tactical plan to ensure successful launch of both rociletinib and rucaparib.• Developed and successfully executed tactical plan (including medical, legal, and regulatory review and OPDP strategy) that included both disease education and branded materials as well as both non-personal and personal promotion. Recognized by field for breadth and quality of tools as well as immediate availability post-launch.• Presented branding plan for hub services to CEO and received buy-in and support to execute plan in 2-3 months.• Collaborated with sales training and leadership to develop and implement access training plan for 100+ field staff. Received satisfaction ratings of 4.7/5.0 for training in post-launch meeting survey. • Selected by VP of Marketing to serve as key member of core launch team with accountability for managed care marketing related activities and input into key launch deliverables including overall brand strategy. • Identified need for and pursued VP-level initiative to lead global market access strategy for launch of rociletinib in Europe including launch sequencing, pricing strategy, and HTA strategy. Recognized by senior leadership for this initiative and invited to serve as core member of EU launch team.• Initiated partnership with medical affairs to convince senior leadership of importance of developing Global Value Dossier (GVD) for successful reimbursement and launch strategy in EU. Received buy-in from senior leadership to co-lead initiative and launch GVD within next 9 months, a process which typically takes 2+ years.

Apr 2015 - Feb 2016

Senior Product Manager, Managed Markets & Patient Access Marketing

• Collaborated with nurse educator team to develop marketing strategy and tactical plan for Esbriet launch; created and delivered both disease education and Esbriet branded launch materials within one month of FDA approval.• Partnered with national account managers and key market access colleagues to create and deliver Payer Value Deck and Formulary Kit, as well as key targeted payer media tactics.• Entrusted to create and deliver time-sensitive marketing materials for mandatory hub targeting both HCPs and patients for Esbriet launch within first two months of hire. Received recognition from senior leadership for high quality output under aggressive timeline.• Problem-solved hub enrollment issues regularly in response to feedback from field and patient access team, with short and long-term solutions identified and implemented, sometimes within record-breaking 2-day turnaround.

Sep 2014 - Mar 2015

Manager, Market Access & Pricing

South San Francisco, Ca, Us

• Led development of Kyprolis® payer value story messaging in preparation for launch, including message testing, to deliver a clear and targeted story that resonated with payers.• Created Kyprolis® Global Payer Plan to facilitate stronger collaboration and communication with Amgen affiliates and drive more effective implementation of Kyprolis® global market access strategy.• Spearheaded global reimbursement assessment for executive leadership to inform a key strategic life cycle management decision. Recommendation was accepted by executive leadership and implemented.• Analyzed health technology assessments, pricing, and reimbursement decision trends for oncology products in US, Europe, Canada, and Australia to support Kyprolis® global launch strategy and life cycle management.• Initiated cross-functional team to improve Kyprolis® returns process reducing turnaround time by 75%.• Managed critical 2014 operating plan budget request process for RAV division, a leadership role previously held by a Senior Director. Operating plan was accepted by executive leadership team and implemented.

Jul 2013 - Aug 2014

Mba Intern - Pulmozyme Marketing

South San Francisco, California, Us

• Created iPad-delivered disease education campaign to increase penetration of Pulmozyme® in key patient segments. Collaborated with sales force to address knowledge gaps among physician population.• Developed tactical launch plan including KPI metrics to determine campaign effectiveness and training plan to ensure sales force comfort and competency utilizing new iPad application.• Partnered with key functional areas: Market Planning and Marketing Science to develop KPI metrics; Training & Development to create sales training strategy; Interactive Marketing to design and implement campaign on iPad.

Jun 2012 - Aug 2012

Intern

Us

• Performed strategic analyses of a portfolio company’s options to advance its antibody platform toward clinical development. Completed market and competitor assessments and modeled investment scenarios. • Developed recommendations to maximize Essex’s return on investment and presented strategy to portfolio company Board of Directors and Essex partnership. Proposal was accepted and is currently being implemented.

Mar 2010 - May 2010

Associate

Close Concerns

• Developed and implemented new marketing strategy and created partnership with Juvenile Diabetes Research Foundation, resulting in 50% increase in patient newsletter circulation and improved patient health outcomes. • Developed relationships with key pharmaceutical, medical device, and biotechnology executives and physicians at global medical conferences in order to maintain thought leadership within industry.• Selected as Managing Editor of monthly industry newsletter distributed to over 200 companies; researched and wrote daily report on market and company impact of diabetes and obesity news.• Built detailed model of client’s potential entry into diabetes market, used to assess major acquisition.• Created in-depth financial modeling training program for all new hires and trained existing associates.

Apr 2009 - Aug 2009

Equity Research Analyst

New York, Ny, Us

• Recognized as research associate on Institutional Investor’s #1 ranked “All-America Research Team” for Media.• Conceived and researched sector-wide and company-specific investment ideas that generated majority of proprietary trading revenue for Media sector.• Researched and wrote initiation reports for Moody’s, Monster, RR Donnelley, and Dice in addition to over 300 detailed earnings notes and research reports on companies in the Media sector.• Presented and advocated investment ideas to sales force, traders, and clients (mutual, pension and hedge funds). • Built and maintained detailed forecasting, company valuation, and industry models.

Sep 2008 - Apr 2009

Equity Research Analyst

Us

• Recognized as research associate on Institutional Investor’s #1 ranked “All-America Research Team” for Media.• Conceived and researched sector-wide and company-specific investment ideas that generated majority of proprietary trading revenue for Media sector.• Researched and wrote initiation reports for Moody’s, Monster, RR Donnelley, and Dice in addition to over 300 detailed earnings notes and research reports on companies in the Media sector.• Presented and advocated investment ideas to sales force, traders, and clients (mutual, pension and hedge funds). • Built and maintained detailed forecasting, company valuation, and industry models.

Aug 2007 - Sep 2008

Summer Analyst

Us

• Researched and summarized pending healthcare legislation (e.g. Health Savings Accounts and Drug Safety)• Projected market impact of pending federal rulemaking and legislation and FDA reviews• Developed risk analysis model for national Medicaid spending and coverage of Xopenex • Wrote weekly research reports that were distributed to Lehman clients and Lehman analysts• Performed in-depth news search and analysis of current healthcare and pharmaceutical policy issues

2006 - 2006

Summer Analyst

Los Angeles, Ca, Us

• Developed list of over 100 target clients for the building products and materials group • Managed data for analysis of REITs and other real estate companies• Organized schedule of financial data regarding 100 largest U.S. homebuilders• Updated list of private equity investors in the aerospace and defense industries for the corporate finance group

2005 - 2005

Legislative Intern

United States Senate

• Researched proposed science and space legislation; Drafted position memos on prospective legislation for the Senator

2005 - 2005

Research Assistant

Los Angeles, Ca, Us

• Received Recognition for Outstanding Scientific Contribution (2002 & 2003)• Cloned vectors for gene therapy of the genetic disorder, Beta-Thalassemia; wrote and presented research papers

2001 - 2003 ~2 yrs

Research Assistant

Ithaca, Ny, Us

• One of three students selected nationally for Biological Research Program

2002 - 2002
5 education records

Jenny Lesser Herbach education

Mba

Harvard Business School

Mphil, Bioscience Enterprise

University Of Cambridge

Ba, Biology

Amherst College

Visiting Student, Biochemistry

University Of Oxford

Education record

Marlborough School
FAQ

Frequently asked questions about Jenny Lesser Herbach

Quick answers generated from the profile data available on this page.

What company does Jenny Lesser Herbach work for?

Jenny Lesser Herbach works for Adventris Pharmaceuticals.

What is Jenny Lesser Herbach's role at Adventris Pharmaceuticals?

Jenny Lesser Herbach is listed as CEO & Co-Founder, Adventris Pharmaceuticals at Adventris Pharmaceuticals.

What is Jenny Lesser Herbach's email address?

AeroLeads has found 2 work email signals at @amunix.com for Jenny Lesser Herbach at Adventris Pharmaceuticals.

What is Jenny Lesser Herbach's phone number?

AeroLeads has found 1 phone signal(s) with area code 650 for Jenny Lesser Herbach at Adventris Pharmaceuticals.

Where is Jenny Lesser Herbach based?

Jenny Lesser Herbach is based in San Francisco, California, United States while working with Adventris Pharmaceuticals.

What companies has Jenny Lesser Herbach worked for?

Jenny Lesser Herbach has worked for Adventris Pharmaceuticals, Amunix, Flx Bio, Inc., Exelixis, and Clovis Oncology.

How can I contact Jenny Lesser Herbach?

You can use AeroLeads to view verified contact signals for Jenny Lesser Herbach at Adventris Pharmaceuticals, including work email, phone, and LinkedIn data when available.

What schools did Jenny Lesser Herbach attend?

Jenny Lesser Herbach holds Mba from Harvard Business School.

What skills is Jenny Lesser Herbach known for?

Jenny Lesser Herbach is listed with skills including Strategy, Financial Modeling, Biotechnology, Oncology, Cross Functional Team Leadership, Analysis, Corporate Finance, and Valuation.

Find 750M verified contacts

Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.